ArticlePloS one2013
Comparing selection on S. aureus between antimicrobial peptides and common antibiotics.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Uncovering the genetic basis ofiScience · 2025Article
- The evolution of antimicrobial peptide resistance in Pseudomonas aeruginosa is severely constrained by random peptide mixtures.PLoS biology · 2024Article
- Antimicrobial peptide glatiramer acetate targets Pseudomonas aeruginosa lipopolysaccharides to breach membranes without altering lipopolysaccharide modification.npj antimicrobials and resistance · 2024Article
- Analyzing resistome in soil and Human gut: a study on the characterization and risk evaluation of antimicrobial peptide resistance.Frontiers in microbiology · 2024Article
- Antimicrobial Peptides in Infectious Diseases and Beyond-A Narrative Review.Life (Basel, Switzerland) · 2023Review
- The pharmacokinetic-pharmacodynamic modelling framework as a tool to predict drug resistance evolution.Microbiology (Reading, England) · 2023Article
- Application of antimicrobial peptides in plant protection: making use of the overlooked merits.Frontiers in plant science · 2023Review
- Antimicrobial Peptide Combination Can Hinder Resistance Evolution.Microbiology spectrum · 2022Article
- Antimicrobial Random Peptide Mixtures EradicateAntibiotics (Basel, Switzerland) · 2022Article
- Evaluation of Three Antimicrobial Peptides Mixtures to Control the Phytopathogen Responsible for Fire Blight Disease.Plants (Basel, Switzerland) · 2021Article
- Enterocin Cross-Resistance Mediated by ABC Transport Systems.Microorganisms · 2021Article
- A Bifunctional Peptide Conjugate That Controls Infections ofMolecules (Basel, Switzerland) · 2021Article
- Random Peptide Mixtures as Safe and Effective Antimicrobials againstACS infectious diseases · 2021Article
- Developing Antimicrobial Synergy With AMPs.Frontiers in medical technology · 2021Review
- Antimicrobial peptides: Application informed by evolution.Science (New York, N.Y.) · 2020Review
- The Synergistic Effect of Mud Crab Antimicrobial Peptides Sphistin and SphFrontiers in cellular and infection microbiology · 2020Article
- Functional Insights From the Evolutionary Diversification of Big Defensins.Frontiers in immunology · 2020Review
- Resistance Evolution Against Antimicrobial Peptides inFrontiers in microbiology · 2020Article
- Statins influence epithelial expression of the anti-microbial peptide LL-37/hCAP-18 independently of the mevalonate pathway.Clinical and experimental immunology · 2019Article
- Application of Synthetic Molecular Evolution to the Discovery of Antimicrobial Peptides.Advances in experimental medicine and biology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
With a diminishing number of effective antibiotics, there has been interest in developing antimicrobial peptides (AMPs) as drugs. However, any new drug faces potential bacterial resistance evolution. Here, we experimentally compare resistance evolution in Staphylococcus aureus selected by three AMPs (from mammals, amphibians and insects), a combination of two AMPs, and two antibiotics: the powerful last-resort vancomycin and the classic streptomycin. We find that resistance evolves readily against single AMPs and against streptomycin, with no detectable fitness cost. However the response to selection from our combination of AMPs led to extinction, in a fashion qualitatively similar to vancomycin. This is consistent with the hypothesis that simultaneous release of multiple AMPs during immune responses is a factor which constrains evolution of AMP resistant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.